- Home
- CALC vs CMBM Comparison
CALC vs CMBM Comparison
Compare CALC & CMBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CALC | CMBM |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3M | 65.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CALC | CMBM |
|---|---|---|
| Price | $6.02 | $1.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 93.6K | ★ 1.3M |
| Earning Date | 11-12-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,215,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.42 | $0.23 |
| 52 Week High | $7.20 | $6.80 |
Technical Indicators
Market Signals| Indicator | CALC | CMBM |
|---|---|---|
| Relative Strength Index (RSI) | 68.87 | 41.29 |
| Support Level | $5.90 | $1.42 |
| Resistance Level | $6.40 | $1.68 |
| Average True Range (ATR) | 0.59 | 0.18 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 64.63 | 9.41 |
Price Performance
Historical ComparisonAbout CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.